openPR Logo
Press release

SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Sepsis

09-18-2013 06:19 PM CET | Health & Medicine

Press release from: SignaBlok, Inc.

Novel First-in-Class Peptide Inhibitor of TREM-1 Shows Promise for Treatment of Cancer and Sepsis

Novel First-in-Class Peptide Inhibitor of TREM-1 Shows Promise for Treatment of Cancer and Sepsis

– Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis –

Shrewsbury, MA, September 17, 2013 – SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

SignaBlok’s innovative approach to cancer and sepsis targets a specific receptor called TREM-1 that is expressed on inflammatory cells, macrophages, and serves as an inflammation amplifier. This receptor is critically involved in cancer, sepsis and other inflammation-related diseases. The approach includes the use of short synthetic peptides that employ novel, ligand-independent mechanisms of TREM-1 inhibition and are designed using a new model of cell signaling, known as the SCHOOL model.

The data were first unveiled at the 2013 American Association of Immunologists Annual Meeting in Honolulu, HI, in talk and poster entitled "A novel ligand-independent peptide inhibitor of TREM-1 modulates the inflammatory response and improves survival in septic mice (P4210)" and at the 2013 Gordon Research Conference on Cancer Nanotechnology in West Dover, VT, in poster entitled "Nature-inspired nanotheranostics for targeted cancer imaging and therapy".

“These results are a crucial animal proof of concept not only for our novel approach to cancer and sepsis that uses a first-in-class, non-toxic TREM-1 inhibitory peptide but also for our strategy of targeted delivery of this peptide to TREM-1-expressing macrophages in vivo using company's proprietary self-assembling nanoparticles”, stated Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. "SignaBlok has successfully leveraged its cutting-edge SCHOOL platform and macrophage-targeted delivery nanotechnology to create a portfolio of highly potent TREM-1 inhibitory peptide formulations."

Dr. Sigalov continued: "There is clear unmet clinical need for new therapies to treat lung cancer and sepsis, and we are very encouraged by the potential of a TREM-1 SCHOOL approach for the treatment of these life-threatening diseases. We believe that our key pre-clinical data set the stage for the development of a potential "magic bullet" therapy not only for sepsis and lung cancer but also for other types of cancers such as pancreatic and colon cancers as well as for a variety of seemingly unrelated inflammation-associated disorders, including radiation sickness, rheumatoid arthritis and psoriasis."

# # #
SignaBlok’s Contact:
Alexander Sigalov, Ph.D., President, Inventor and Founder: (203) 505-3807; sigalov@signablok.com

About SignaBlok, Inc:
SignaBlok, Inc. is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy. Additional information about SignaBlok is available at www.signablok.com.

SignaBlok, Inc.
P.O. Box 4064
Shrewsbury, MA 01545

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Sepsis here

News-ID: 270732 • Views:

More Releases for SignaBlok

SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
Shrewsbury, MA, January 10, 2012 – SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, today announced that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s novel approach to the prevention and treatment of sepsis (blood poisoning), a serious medical condition characterized by a whole-body inflammatory state that often leads to death, and to establish proof of concept for this strategy in vivo. SignaBlok’s